Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

News Daily News

SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients

L.A. McKeown

October 23, 2024

News Daily News

Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 Diabetes

Michael O'Riordan

August 19, 2024

News Daily News

FINEARTS-HF: Topline Results Support Role for Finerenone in Mildly Reduced or Preserved EF

L.A. McKeown

August 05, 2024

News Daily News

Semaglutide Winning Streak Continues in CKD With FLOW

Shelley Wood

March 06, 2024

News Daily News

‘Redlining’ of Neighborhoods Left a Legacy of Poorer CV Health

L.A. McKeown

July 04, 2022

News Daily News

Comorbidities May Drive PAD Procedural Outcomes in Black Patients

L.A. McKeown

June 23, 2022

News Daily News

New Revascularization Guidelines Plug Radial Access, Staged PCI, and Shorter DAPT

Michael O'Riordan

December 09, 2021

News Daily News

FDA Approves Finerenone for Adults With CKD and Type 2 Diabetes

Yael L. Maxwell

July 09, 2021

News Daily News

Finerenone Cuts CV Events in CKD Patients With Diabetes: FIGARO-DKD

Michael O'Riordan

May 11, 2021

News Daily News

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Shelley Wood

December 17, 2020

News Daily News

Similar MACCE in Coronary Patients With Diabetes and CKD Treated With CABG or PCI

L.A. McKeown

January 31, 2019

News Daily News

Statin Benefits: Yes for CVD but No for Everything Else, Says New Review

Michael O'Riordan

October 08, 2018

News Daily News

Dapagliflozin Gets Partial Win in DECLARE-TIMI 58

Todd Neale

October 02, 2018

News Daily News

SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function

Todd Neale

July 02, 2018

News Daily News

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

Michael O'Riordan

August 04, 2017

News Daily News

Pre-PCI Trimetazidine Strategy Reduces CIN, Myocardial Injury in Diabetic Patients with Mild-to-Moderate CKD

May 30, 2014

News Daily News

高风险亚组从瑞舒伐他汀中获得肾脏保护

Caitlin E. Cox

October 11, 2013

News Daily News

High-Risk Subgroups Derive Kidney Protection from Rosuvastatin

Caitlin E. Cox

October 11, 2013

Advertisement

SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients

Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 Diabetes

FINEARTS-HF: Topline Results Support Role for Finerenone in Mildly Reduced or Preserved EF

Semaglutide Winning Streak Continues in CKD With FLOW

‘Redlining’ of Neighborhoods Left a Legacy of Poorer CV Health

Comorbidities May Drive PAD Procedural Outcomes in Black Patients

New Revascularization Guidelines Plug Radial Access, Staged PCI, and Shorter DAPT

FDA Approves Finerenone for Adults With CKD and Type 2 Diabetes

Finerenone Cuts CV Events in CKD Patients With Diabetes: FIGARO-DKD

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Similar MACCE in Coronary Patients With Diabetes and CKD Treated With CABG or PCI

Statin Benefits: Yes for CVD but No for Everything Else, Says New Review

Dapagliflozin Gets Partial Win in DECLARE-TIMI 58

SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

Pre-PCI Trimetazidine Strategy Reduces CIN, Myocardial Injury in Diabetic Patients with Mild-to-Moderate CKD

高风险亚组从瑞舒伐他汀中获得肾脏保护

High-Risk Subgroups Derive Kidney Protection from Rosuvastatin

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content